MBRC-101 is under clinical development by MBrace Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MBRC-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MBRC-101 overview

MBRC-101 is under development for the treatment of solid tumors including non-small cell lung cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), squamous cell carcinoma of the head and neck and triple-negative breast cancer (TNBC). The therapeutic candidate is anti-EphA5 monomethyl auristatin E (MMAE) antibody drug conjugate and is being developed based on Selection of Phage-displayed Accessible Recombinant Targeted Antibodies (SPARTA) technology.

MBrace Therapeutics overview

MBrace Therapeutics is developing antibody drug conjugates against two novel cancer targets using human antibodies selected from SPARTA methodology. The company is headquartered in San Diego, California, the US.

For a complete picture of MBRC-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.